The Investment Column: Key trials on track for British Biotech
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.When British Biotech, the biggest hope in the UK's faltering biotech sector, announces results, investors want to hear only one thing: progress on marimastat, its cancer drug. In such a crestfallen sector the desire for a quantum leap forward in news is understandable. Yesterday's interims from British Bio could offer no fireworks, with losses pounds 4m deeper at pounds 20m, but did show that marimastat trials, the largest pre-registration cancer trials ever conducted, are on track and gaining serious weight.
In a massive study, marimastat is being tested on six different tumour types, in combination with cytotoxics and eventually on early stage cancers. Familiarising doctors with marimastat ahead of its registration and demonstrating its potential in as many cancers as possible could make this a billion- dollar seller. Doctors frequently prescribe trusted cancer drugs more broadly than their indicated use.
As well as building up a sales force in Europe and eventually in the US, British Bio plans to buy in "accessories" such as like anti-nausea and anti-pain drugs to provide oncologists with a full cancer kit. With marimastat at least 18 months away from filing, such massive up-front investment raises the stakes.
True, British Bio has plenty of cash and a lead drug, Zacutex for pancreatitis, which could be filed in Europe in early 1998, but if marimastat fails British Bio will struggle to recover. But serious drugs require serious backing. Glaxo's Zantac became a blockbuster not because it was a such a great ulcer remedy, but because every doctor knew about it. British Biotech's shares down 2.5p to 103p, near their year low, are a buy for those who understand the risks.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments